Clinical endocrinology · 1994
Pyridostigmine induced growth hormone release in mania: focus on the cholinergic/somatostatin system.
Сравнительное исследованиеСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dinan T G, O'Keane V, Thakore J
Аннотация
OBJECTIVE: The release of growth hormone (GH) from the anterior pituitary is partly under cholinergic control. Pyridostigmine, the acetylcholinesterase inhibitor, releases GH by this mechanism. Pyridostigmine/GH responses have been reported as enhanced in depression. The aim of the current study was to examine such responses during a manic episode.
DESIGN: A between subjects design was employed.
SUBJECTS: Seven male manic patients and seven male healthy controls were studied. They were matched in terms of age and body mass index.
MEASUREMENTS: GH response to pyridostigmine (120 mg) challenge was measured as the net increase above baseline. Cortisol levels were also measured.
RESULTS: Release of GH in the manic patients was significantly enhanced and their baseline cortisol levels were elevated.
CONCLUSIONS: These results demonstrate enhanced pyridostigmine/GH responsiveness in mania which may be due to enhanced somatostatin tone or increased cholinergic receptor responsivity.
DESIGN: A between subjects design was employed.
SUBJECTS: Seven male manic patients and seven male healthy controls were studied. They were matched in terms of age and body mass index.
MEASUREMENTS: GH response to pyridostigmine (120 mg) challenge was measured as the net increase above baseline. Cortisol levels were also measured.
RESULTS: Release of GH in the manic patients was significantly enhanced and their baseline cortisol levels were elevated.
CONCLUSIONS: These results demonstrate enhanced pyridostigmine/GH responsiveness in mania which may be due to enhanced somatostatin tone or increased cholinergic receptor responsivity.